That’s what The Independent, a UK newspaper, is writing today. Supposedly, a US medical journal will this week publish a major study that the drugmaker says will back up its fierce defence of Avandia, although there’s no attribution for the info.

The results of the Glaxo-commissioned study of 30,000 diabetes patients in a real-world setting, to be published as soon as tomorrow, is expected to show that Avandia has a safety profile similar to rival treatments. But the identity of the American publication is a closely guarded secret because of fears that it would be inundated with calls if it was revealed.

Of course, Glaxo hopes the timing of such a study may blunt what is surely going to be a difficult day on Wednesday, when a Congressional hearing is held into the way Glaxo and the FDA handled Avandia safety risks.

Hat tip to PharmaGossip